What is the recommended dosing regimen for tofacitinib (Xeljanz) in adults with rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, including dose adjustments for renal or hepatic impairment and interactions with strong CYP3A4 or CYP2C19 inhibitors?

Tofacitinib Dosing Recommendations

For rheumatoid arthritis and psoriatic arthritis, use tofacitinib 5 mg twice daily (or 11 mg extended-release once daily); for ulcerative colitis, initiate with 10 mg twice daily for 8 weeks induction, then reduce to 5 mg twice daily for maintenance. 1, 2

Standard Dosing by Indication

Rheumatoid Arthritis & Psoriatic Arthritis

• Standard dose: 5 mg twice daily (immediate-release) OR 11 mg once daily (extended-release) 1, 2
• Can be used as monotherapy or combined with methotrexate 3
• The 10 mg twice daily dose carries significantly higher risks of venous thromboembolism and serious infections, particularly in patients >65 years with cardiovascular risk factors 1

Ulcerative Colitis

• Induction: 10 mg twice daily (or 22 mg XR once daily) for minimum 8 weeks 2
  • May extend to 16 weeks if adequate response not achieved by week 8
  • Discontinue if no adequate response after 16 weeks
• Maintenance: 5 mg twice daily (or 11 mg XR once daily) 2
  • Use lowest effective dose to maintain response
  • For loss of response during maintenance, may consider temporary increase to 10 mg twice daily with careful benefit-risk assessment 4, 2

Psoriasis (Off-Label)

• 5 mg twice daily OR 10 mg twice daily 3
• The 10 mg dose shows greater efficacy but substantially higher infection and cytopenia risks 3

Dose Adjustments for Renal Impairment

Moderate renal impairment (CrCl 30-50 mL/min): 1, 2

• RA/PsA: Reduce to 5 mg once daily
• UC induction: 5 mg twice daily (or 11 mg XR once daily)
• UC maintenance: 5 mg once daily

Severe renal impairment (CrCl <30 mL/min): 1, 2

• RA/PsA: 5 mg once daily
• UC: 5 mg once daily for maintenance; XELJANZ XR not recommended
• Hemodialysis patients: Administer dose after dialysis session; no supplemental doses needed if taken before dialysis

Mild renal impairment (CrCl >50-80 mL/min): No dose adjustment required 2

The rationale for these reductions is that tofacitinib undergoes 30% renal excretion, with AUC increasing by 143% in moderate impairment and 223% in severe impairment compared to normal renal function 5.

Dose Adjustments for Hepatic Impairment

Moderate hepatic impairment (Child-Pugh B): 3, 1, 2

• RA/PsA: 5 mg once daily
• UC induction: 5 mg twice daily (or 11 mg XR once daily)
• UC maintenance: 5 mg once daily; XELJANZ XR not recommended

Severe hepatic impairment (Child-Pugh C): Tofacitinib is not recommended 3, 1, 2

Mild hepatic impairment (Child-Pugh A): No dose adjustment required 2

Drug Interaction Dose Adjustments

Strong CYP3A4 Inhibitors (e.g., ketoconazole)

Reduce to 5 mg once daily for all indications 3, 1, 2

Moderate CYP3A4 Inhibitors + Strong CYP2C19 Inhibitors (e.g., fluconazole)

Reduce to 5 mg once daily for all indications 3, 1, 2

Strong CYP2C19 Inhibitors Alone

No dose adjustment required 2

Moderate CYP3A4 or CYP2C19 Inhibitors Alone

No dose adjustment required 2

Important caveat: Tofacitinib is metabolized primarily via CYP3A4 (with 30% renal excretion), making it susceptible to interactions with CYP3A4 modulators 1, 6. Rifampicin increases tofacitinib metabolism and may require dose increase, though specific recommendations are not established 1.

Laboratory-Based Dose Modifications

Discontinue Tofacitinib If:

• Lymphocyte count <500 cells/mm³ (confirmed by repeat testing) 3, 2
• Absolute neutrophil count (ANC) <500 cells/mm³ 3, 2
• Hemoglobin <8 g/dL or decrease ≥2 g/dL (confirmed by repeat testing) 3, 2

Hold Tofacitinib If:

• ANC 500-1000 cells/mm³: Interrupt dosing until ANC >1000 cells/mm³ 3, 2
  • For UC patients on 10 mg twice daily: may reduce to 5 mg twice daily, then increase back when ANC >1000 2

Do Not Initiate Tofacitinib If:

• Lymphocyte count <500 cells/mm³
• ANC <1000 cells/mm³
• Hemoglobin <9 g/dL 3

Special Populations & Considerations

Pediatric Polyarticular Juvenile Idiopathic Arthritis

Weight-based dosing applies (not detailed in adult-focused evidence provided) 2

Elderly Patients (≥65 years)

Use standard dosing but exercise heightened caution, particularly avoiding 10 mg twice daily due to significantly elevated serious infection rates compared to TNF inhibitors 1. The European Medicines Agency recommends using tofacitinib in elderly patients with cardiovascular risk factors only if no alternative exists 1.

Pregnancy & Lactation

Tofacitinib is teratogenic in animal studies and contraindicated during breastfeeding 1. Use only if potential benefit justifies fetal risk 3. Recommend 4-week gap after last dose before attempting conception 1.

Cardiovascular Risk Factors

The 10 mg twice daily dose is associated with increased venous thromboembolism (VTE) and pulmonary embolism, particularly in patients with cardiovascular risk factors 1, 7. Use with extreme caution in patients with VTE history or risk factors (obesity, hormone replacement therapy, advanced age) 1.

Clinical Pearls

Switching formulations: Patients on 5 mg twice daily immediate-release can switch to 11 mg XR once daily the day after last immediate-release dose; those on 10 mg twice daily can switch to 22 mg XR once daily 2.

Herpes zoster prophylaxis: Consider Shingrix vaccination before initiating tofacitinib due to elevated herpes zoster risk 3.

Avoid live vaccines while on tofacitinib 3.

Do not combine with potent immunosuppressants (azathioprine, cyclosporine) or biologics 3, 1.

Extended induction in UC: Real-world data suggests extending induction to 16 weeks (rather than standard 8 weeks) significantly improves clinical response rates (69% vs 45% at week 16) 8. Consider this approach in patients with incomplete response at week 8.

Dose de-escalation caution: In UC, approximately 25-29% of patients de-escalated from 10 mg to 5 mg twice daily lose response, with only 63% recapturing response upon re-escalation 4. Monitor closely after any dose reduction.